From VICTORIA to VICTOR: Where Vericiguat Fits in HFrEF Care
Background. Vericiguat, an oral soluble guanylate cyclase stimulator, augments impaired NO-sGC-cGMP signaling in heart failure with reduced ejection fraction (HFrEF). The pivotal VICTORIA trial enrolled high-risk patients with recent worsening heart failure (WHF) and showed a reduction in the compos...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Kazimierz Wielki University
2025-09-01
|
| Serie: | Journal of Education, Health and Sport |
| Soggetti: | |
| Accesso online: | https://apcz.umk.pl/JEHS/article/view/65624 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|